Major Thalassemia, Screening or Treatment: An Economic Evaluation Study in Iran

Document Type : Original Article


1 Department of Public Health, School of Public Health, Maragheh University of Medical Sciences, Maragheh, Iran

2 Department of Health Management & Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

3 Department of Healthcare Administration, School of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

4 Department of Health Information Technology, Amol Faculty of Paramedical Sciences, Mazandaran University of Medical Sciences, Sari, Iran

5 Department of Health Management and Social Development Research Center, Faculty of Health, Golestan University of Medical Sciences, Gorgan, Iran

6 Department of Environmental Health Research Center, Faculty of Health, Golestan University of Medical Sciences, Gorgan, Iran


Beta-thalassemia minor and thalassemia major are an autosomal recessive disease with hypochromic, microcytic anemia, and morbidities, Today, therapeutic advances have significantly improved the life expectancy of thalassemia major patients, but at the cost of financial toxicity. The present study aimed to investigate the possibility of increasing the funding for thalassemia screening programs and comparing the cost-effectiveness of screening for thalassemia in the treatment of the patients.
In this study, screening for thalassemia minor was compared with the treatment of thalassemia major patients. A decision tree model was used for analysis. A hospital database, supplemented with a review of published literature, was used to derive input parameters for the model. A lifetime study horizon was used and future costs and consequences were discounted at 3%. The approach of purchases of services was used to evaluate the screening test costs for patients with thalassemia major. Also, a bottom-up method was applied to estimate other screening and treatment costs. All the costs were calculated over one year. The number of gained quality-adjusted life years (QALYs) was calculated using the EQ-5D questionnaire in the evaluated patients.
In this study, 26.97 births of patients with thalassemia major were prevented by screening techniques. On the other hand, total screening costs for patients with thalassemia major were estimated equal to US$ 879 879, while the costs of preventing the birth of each thalassaemia major patient was US$ 32 624 by screening techniques. In comparison, the cost of managing a patient with thalassemia major is about US$ 136 532 per year. The life time QALYs for this is 11.8 QALYs. Results are presented using a societal perspective. Incremental cost per QALY gained with screening as compared with managing thalassaemia major was US$ 11 571.
Screening is a long-term value for money intervention that is highly cost effective and its long-term clinical and economic benefits outweigh those of managing thalassaemia major patients.


  1. Lazarte SS, Mónaco ME, Terán MM, Haro AC, Achem MEL, Issé BA. Foxo3 gene expression and oxidative status in beta-thalassemia minor subjects. Rev Bras Hematol Hemoter. 2017;39(2):115-121. doi:10.1016/j.bjhh.2017.01.005
  2. Azimi A, Alibakhshi R, Hayati H, Tahmasebi S, Alimoradi S. IVS-II-648/649 (-T) (HBB: c.316-202del) triggers a novel β-thalassemia phenotype. Hemoglobin. 2017;41(1):44-46. doi:10.1080/03630269.2017.1308376
  3. Vincent O, Oluwaseyi B, James B, Saidat L. Coinheritance of B-thalassemia and sickle cell anaemia in Southwestern Nigeria. Ethiop J Health Sci. 2016;26(6):517-522. doi:10.4314/ejhs.v26i6.3
  4. Koh DXR, Raja Sabudin RZA, Mohd Yusoff M, et al. Molecular characterisation of α- and β-thalassaemia among indigenous Senoi Orang Asli communities in Peninsular Malaysia. Ann Hum Genet. 2017;81(5):205-212. doi:10.1111/ahg.12201
  5. Muhammad R, Shakeel M, Rehman SU, Lodhi MA. Population-based genetic study of β-thalassemia mutations in Mardan Division, Khyber Pakhtunkhwa province, Pakistan. Hemoglobin. 2017;41(2):104-109. doi:10.1080/03630269.2017.1330210
  6. Chiodi E, Nardozza M, Gamberini MR, et al. Left ventricle remodeling in patients with β-thalassemia major. An emerging differential diagnosis with left ventricle noncompaction disease. Clin Imaging. 2017;45:58-64. doi:10.1016/j.clinimag.2017.05.010
  7. Fahmey SS, Taha G, El-Refaey A, Adly S. Skin disorders in Egyptian children with β-thalassemia major. J Trop Pediatr. 2018;64(2):104-109. doi:10.1093/tropej/fmx035
  8. Elalfy MS, Aly RH, Azzam H, et al. Neurocognitive dysfunction in children with β thalassemia major: psychometric, neurophysiologic and radiologic evaluation. Hematology. 2017;22(10):617-622. doi:10.1080/10245332.2017.1338212
  9. Pepe A, Rossi G, Bentley A, et al. Cost-utility analysis of three iron chelators used in monotherapy for the treatment of chronic iron overload in β-thalassaemia major patients: an Italian perspective. Clin Drug Investig. 2017;37(5):453-464. doi:10.1007/s40261-017-0496-1
  10. Koren A, Profeta L, Zalman L, et al. Prevention of β thalassemia in Northern Israel-a cost-benefit analysis. Mediterr J Hematol Infect Dis. 2014;6(1):e2014012. doi:10.4084/mjhid.2014.012
  11. Esmaeilzadeh F, Azarkeivan A, Emamgholipour S, et al. Economic burden of thalassemia major in Iran, 2015. J Res Health Sci. 2016;16(3):111-115.
  12. Lai K, Huang G, Su L, He Y. The prevalence of thalassemia in mainland China: evidence from epidemiological surveys. Sci Rep. 2017;7(1):920. doi:10.1038/s41598-017-00967-2
  13. Goulas V, Kourakli-Symeonidis A, Camoutsis C. Comparative effects of three iron chelation therapies on the quality of life of greek patients with homozygous transfusion-dependent Beta-thalassemia. ISRN Hematol. 2012;2012:139862. doi:10.5402/2012/139862
  14. Jagannath VA, Fedorowicz Z, Al Hajeri A, Sharma A. Hematopoietic stem cell transplantation for people with ß-thalassaemia major. Cochrane Database Syst Rev. 2014(10):CD008708. doi:10.1002/14651858.CD008708.pub3
  15. Moayedi-Nia S, Bayat Jozani Z, Esmaeeli Djavid G, et al. HIV, HCV, HBV, HSV, and syphilis prevalence among female sex workers in Tehran, Iran, by using respondent-driven sampling. AIDS Care. 2016;28(4):487-490. doi:10.1080/09540121.2015.1109582
  16. Tari K, Alikhani S, Abbaszadehdibavar M, Kianinodeh F, Karami F, Atashi A. Evaluation of the sensitivity and specificity of MCH and MCV for screening of β thalassemia minor. Int J Biomed Public Health. 2018;1(4):184-186. doi:10.22631/ijbmph.2018.119048.1021
  17. Miri M, Tabrizi Namini M, Hadipour Dehshal M, et al. Thalassemia in Iran in last twenty years: the carrier rates and the births trend. Iran J Blood Cancer. 2013;6(1):11-17.
  18. Altman DG. Practical Statistics for Medical Research. CRC Press; 1990:456.
  19. Goudarzi R, Zeraati H, Akbari Sari A, Rashidian A, Mohammad K. Population-based preference weights for the EQ-5D health states using the visual analogue scale (VAS) in Iran. Iran Red Crescent Med J. 2016;18(2):e21584. doi:10.5812/ircmj.21584
  20. Lai K, Jia S, Yu S, Luo J, He Y. Genome-wide analysis of aberrantly expressed lncRNAs and miRNAs with associated co-expression and ceRNA networks in β-thalassemia and hereditary persistence of fetal hemoglobin. Oncotarget. 2017;8(30):49931-49943. doi:10.18632/oncotarget.18263
  21. Hatam N, Esmaelzade F, Mirahmadizadeh A, et al. Cost-effectiveness of rabies post exposure prophylaxis in Iran. J Res Health Sci. 2014;14(2):122-127.
  22. Ahmadnezhad E, Sepehrvand N, Jahani FF, et al. Evaluation and cost analysis of national health policy of thalassaemia screening in West-Azerbaijan province of Iran. Int J Prev Med. 2012;3(10):687-692.
  23. Leung KY, Lee CP, Tang MH, et al. Cost-effectiveness of prenatal screening for thalassaemia in Hong Kong. Prenat Diagn. 2004;24(11):899-907. doi:10.1002/pd.1035
  24. Ginsberg G, Tulchinsky T, Filon D, Goldfarb A, Abramov L, Rachmilevitz EA. Cost-benefit analysis of a national thalassaemia prevention programme in Israel. J Med Screen. 1998;5(3):120-126. doi:10.1136/jms.5.3.120
  25. Sattari M, Sheykhi D, Nikanfar A, et al. The financial and social impact of thalassemia and its treatment in Iran. Pharm Sci. 2012;18(3):171-176.
  26. Riewpaiboon A, Nuchprayoon I, Torcharus K, Indaratna K, Thavorncharoensap M, Ubol BO. Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children. BMC Res Notes. 2010;3:29. doi:10.1186/1756-0500-3-29
  27. Ho WL, Lin KH, Wang JD, et al. Financial burden of national health insurance for treating patients with transfusion-dependent thalassemia in Taiwan. Bone Marrow Transplant. 2006;37(6):569-574. doi:10.1038/sj.bmt.1705287
  28. Leelahavarong P, Chaikledkaew U, Hongeng S, Kasemsup V, Lubell Y, Teerawattananon Y. A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand. BMC Health Serv Res. 2010;10:209. doi:10.1186/1472-6963-10-209
  29. Naghavi M, Abolhassani F, Pourmalek F, et al. The burden of disease and injury in Iran 2003. Popul Health Metr. 2009;7:9. doi:10.1186/1478-7954-7-9
  30. World Bank. GDP per capita (current US$). World Bank website. Updated 2020.
Volume 11, Issue 7
July 2022
Pages 1112-1119
  • Receive Date: 13 October 2019
  • Revise Date: 27 December 2020
  • Accept Date: 12 January 2021
  • First Publish Date: 03 February 2021